Transaction · 0001193125-26-389892

Karlin Daniel

Karlin Daniel, CMO, reported a transaction classified as grant at Definium Therapeutics, Inc. involving 200000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 803699.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
DFTXDefinium Therapeutics, Inc.
Trade date
Sep 14, 2026
Filing date
Sep 14, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded200k$0.00 per share
Holdings after803kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

DFTX price since this filing

Daily closing prices, with the filing date and available return windows
DFTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.9%1w ago +12.0%1d ago -3.4%
Returns since7d -2.4%30d -14.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001193125-26-389892
Common Shares
Transaction date
Sep 14, 2026
Filed Sep 14, 2026, 12:30 PM · 0d delay
Shares
200,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
803,699 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through Ma…

  2. F2

    Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.

Original filing · 0001193125-26-389892
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

DFTX